Car t-cell therapy for advanced multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have multiple myeloma that has come back after treatment or did not respond to your last treatment.
- You must have already tried at least 3 different types of treatment, including a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), and a CD38-targeted antibody (like daratumumab).
- Your cancer must be measurable with a blood or urine test, or you may join for safety monitoring if it is not.
- You should be able to manage daily activities with some help (ECOG 0-2).
- Your heart, liver, kidneys, and lungs need to be working well enough for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called VV169, a type of CAR T cell therapy, for people with multiple myeloma that has returned or stopped responding to previous treatments. The goal is to see if it is safe and if it can help fight the cancer.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a special type of immune therapy called CAR T cells, which are made from your own blood cells and then given back to you to fight the cancer. It is for people with multiple myeloma who have not gotten better with other treatments or whose cancer has come back.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.